Enterprise Value

750M

Cash

551.4M

Avg Qtr Burn

-23.6M

Short % of Float

10.34%

Insider Ownership

0.79%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Update

Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details
Renal cell carcinoma, Cancer, Prostate cancer

Phase 2

Data readout

Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details
Cancer, Non-small cell lung carcinoma

Phase 2

Initiation

XmAb662 (IL12-Fc) Details
Cancer, Solid tumor/s

Phase 1

Data readout

Plamotamab (CD20xCD3) Details
Non-Hodgkin lymphoma, B-cell malignancies, Chronic lymphocytic leukemia

Phase 1

Update

XmAb564 (IL-2-Fc) Details
Autoimmune disease, Psoriasis, Atopic dermatitis

Phase 1a

Update

Vibecotamab (CD123xCD3) Details
Acute myeloid leukemia

Failed

Discontinued

Tidutamab (SSTR2xCD3) Details
Cancer, Neuroendocrine tumor, Gastrointestinal stromal tumors

Failed

Discontinued